Clinical Trials Browser

Phase 1 × Fallopian Tube Neoplasms × Colony-Stimulating Factors × Clear all

NCT02470559 2016-02-17

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Phase 1 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms